Antonio La Marca

No ORCID on file · 32 papers in corpus · active 1998-2026

Study types

  • article 15
  • review 7
  • other 5
  • book-chapter 2
  • letter 1

Condition tags

  • endometriosis 14
  • adenomyosis 8
  • infertility 7
  • chronic_pelvic_pain 5
  • die_deep_infiltrating 5
  • dysmenorrhea 4
  • dyspareunia 2
  • endometrioma 2
article 2005
Evidence for cycle-dependent expression of follicle-stimulating hormone receptor in human endometrium
·doi:10.1080/09513590500402756

OBJECTIVE: It was the purpose of the present study to investigate whether human endometrium expresses follicle-stimulating hormone (FSH) receptor mRNA and peptide, and whether this expression is regulated in a cycle-dependent manner in endo…

article 2005
Progestin effects on epidermal growth factor receptor (EGFR) endometrial expression in normal and hyperplastic endometrium
·doi:10.1016/j.ijgo.2005.02.003

The epidermal growth factor (EGF) and its receptor (EGFR) are involved in the control of the human endometrial growth [1]. The EGFR endometrial expression is up-regulated by estrogens [2]. The endometrial EGFR increases during the follicula…

letter 2003
Hemodynamic effect of danazol therapy in women with uterine leiomyomata
·doi:10.1016/s0015-0282(03)00070-0
review 2002
A Benefit-Risk Assessment of Medical Treatment for Uterine Leiomyomas
·doi:10.2165/00002018-200225110-00002
article 1999
Low-dose danazol after combined surgical and medical therapy reduces the incidence of pelvic pain in women with moderate and severe endometriosis
Human Reproduction ·doi:10.1093/humrep/14.9.2371

The most effective therapy for endometriosis is a matter for debate. The aim of the present randomized study was to evaluate the efficacy of low doses of danazol on recurrence of pelvic pain in patients with moderate or severe endometriosis…

article 1999
Short-Term Treatment of Uterine Fibromyomas with Danazol
·doi:10.1159/000010118

The aim of this study was to evaluate the effects of danazol in reducing the volume of fibromyomas and in the treatment of associated symptoms. Twenty women (34-42 years) with uterine fibromyomas were treated with 400 mg/day of danazol for …

article 1998
Correspondence
·doi:10.1016/s0015-0282(98)00369-0